Introduction: Polycystic ovary syndrome (PCOS) is a disorder that substantially affects women’s health. It is particularly diagnosed in young patients. Women with PCOS are burdened with excessive weight gain, overweight and obesity (74%) compared to a healthy female population. Excessive weight influences psychological state and emotional well-being, whereas in the meantime, psychological and behavioral dysfunction is increasingly being diagnosed among patients with PCOS. Aim: To assess depressive symptoms and emotional control among women with PCOS in relation to BMI. Methods: The study was conducted among 671 self-reported PCOS women. The standardized Beck Depression Inventory (BDI) was used to assess depressive disorders. Emotion control was assessed using the Courtauld Emotional Control Scale (CECS). Results: Moderate and severe depressive symptoms were more common in PCOS women with abnormal BMI compared to normal BMI subjects (p < 0.01). In total, 27.1% of obese women had moderate depression and 28.8% had severe depression. Among overweight women, 19.9% suffered from moderate and 25% from severe depressive symptoms. Underweight women also reported moderate (25.6%) and severe (33.3%) depressive signs. There were no statistically significant differences between the body weight of the women studied and the CECS scores. Conclusions: Depressive symptoms are more common in women with PCOS and abnormal BMI than in women with PCOS and proper BMI. The severity of depressive symptoms increases with BMI, but underweight women with PCOS are also at risk of depressive disorders. The level of suppression of negative emotions is independent of BMI in women with PCOS.

CDKL5 deficiency disorder (CDD) is a developmental encephalopathy caused by pathogenic variants in the X-linked cyclin-dependent kinase 5 (CDKL5) gene. This rare disorder occurs more frequently in females than in males. The incidence is estimated to be approximately 1: 40,000–60,000 live births. So far, 50 cases have been described in boys. The clinical course in males tends to be more severe and is often associated with death in the first or second decade of life. The authors present an unreported 2.5-year-old male patient with drug-resistant epilepsy who was diagnosed with a de novo mutation in the CDKL5 gene. First seizures developed in the fifth week of life and have progressed steadily since then. The child’s psychomotor development was strongly delayed, and generalized hypotonia was noticed since birth. Brain MRI showed areas of incomplete myelination, posterior narrowing of the corpus callosum, a pineal cyst of up to 3 mm, and open islet lids. Intensive antiseizure medications (ASMs), a ketogenic diet, and steroid therapy were not successful. Short-term improvement was achieved with the implantation of a vagal nerve stimulator (VNS). Due to the progressive course of the disease, the boy requires frequent modification of ASMs.

Introduction Parkinson's disease (PD) poses significant challenges due to its complex array of motor and non-motor symptoms, impacting patients' quality of life. While traditional pharmacological treatments focus on motor symptoms, non-pharmacological interventions, including physical and dance therapy, offer alternative approaches. Aim of the Study This study aims to evaluate the therapeutic potential of physical and dance therapy, including tango, in managing motor symptoms and improving overall well-being in individuals with PD. It seeks to compare these interventions with traditional treatments and explore their efficacy. State of Knowledge Parkinson's disease management involves a combination of pharmacological and non-pharmacological approaches. Traditional treatments target motor symptoms but have limitations. Non-pharmacological interventions, such as deep brain stimulation and physical therapy, complement traditional treatments. Dance therapy, including tango, shows promise in improving motor function and quality of life. Conclusions Physical and dance therapy, including tango, offer promising avenues for managing motor symptoms and enhancing quality of life in PD patients. While traditional treatments remain essential, non-pharmacological interventions provide valuable alternatives. Further research is needed to refine intervention parameters and compare their effectiveness comprehensively. Overall, these therapies present holistic approaches to PD management, addressing both motor and non-motor symptoms for improved patient outcomes.

Introduction: Patellar tendinopathy, commonly referred to as jumper’s knee, presents as pain and dysfunction in the patellar tendon, predominantly affecting athletes engaged in jumping sports. The symptoms of patellar tendinopathy not only impact sports involvement but also interfere with activities of daily living, such as climbing stairs and sitting for extended periods, which in turn affects overall well-being. A variety of treatment options are available, encompassing both conservative approaches, such as modifying activity levels and undergoing physical therapy, and surgical methods. Aim of the study: The objective of this study is to review the current literature regarding the incidence, risk factors and currently available treatment methods for patellar tendinopathy. In addition, the aim is to present a summary of the knowledge and information collected so far in this area in a concise and accessible format. State of knowledge: The epidemiology and mechanisms of patellar tendinopathy are already well documented and described. The statistics regarding the incidence of patellar tendinopathy among athletes in the given fields are sufficiently consistent with each other. The existing literature provides insights into the efficacy of various therapeutic approaches for patellar tendinopathy, yet it is limited in scope. Conclusion: This review acknowledges that recent advancements in research have led to a fuller understanding of epidemiology and improvement of treatment methods for patellar tendinopathy. Despite this, a single therapy is not sufficient for optimal outcomes. Therefore, it is recommended that a comprehensive approach to conservative treatment be adopted. Further research and clinical trials are essential for the generation of reliable conclusions.

We aimed to evaluate the rate and risk factors of in-hospital mortality in patients undergoing coronary angiography/angioplasty with IABP use as support. We included 214 patients (mean age: 67.5 ± 7.5 years, M/F: 143/71) with an IABP used as the periprocedural support between 2012 and 2020. The main indications for an IABP were cardiogenic shock (143 pts; 66.8%: 55 survivors (51.9%)/88 non-survivors (81.5%); p < 0.001) and infarction with an initial significant impairment of ventricular function (34 pts; 15.9%: 21 (19.8%)/13 (12%); p = 0.12). In-hospital death was the endpoint of this study. In-hospital death occurred in 108 (50.5%, M/F: 69.4%/30.6%) patients. The mean hospitalization time was 7 days (2–13); deaths occurred more frequently on the first day after the procedure (1 (1–3 days) vs. 3 (1–8), p < 0.001); and the mean hospitalization time was 2 days (1–6) for non-survivors vs. 11 days (7–17) for survivors (p < 0.001). Regarding the patients who did not survive, they were older (69 vs. 66.5, p = 0.043), their LVEF was lower (0–15%: 15 (13.9%) vs. 12 (11.3%); 16–40%: 73 (67.6%) vs. 65 (61.3%); >40%: 14 (13%) vs. 29 (27.4%); p = 0.007), and hyperlipidemia was less common (30 (27.8%) vs. 55 (51.9%) pts, p = 0.001) than in those who survived. The IABP is still a method for cardiac support; however, mortality limits its use.

Introduction and objective: Food allergy in infants is a major health problem in urbanised countries, the incidence of which is increasing and is a challenge for both parents and doctors. In the first months of life, a child’s body is particularly sensitive to allergic reactions, therefore...